| Literature DB >> 35324846 |
Paolo Emidio Crisi1, Francesca De Santis1, Giovanni Aste1, Pietro Giorgio Tiscar1, Francesco Mosca1, Agostina Gasparini1, Andrea Felici2, Laura Ferroni2, Arianna Miglio3, Morena Di Tommaso1, Alessia Luciani1.
Abstract
The placement of peripheral intravenous catheters (PIVC) is potentially associated with complications that negatively impact healthcare. Our study investigated factors associated with the occurrence of PIVC-related complications in dogs and cats at a Veterinary Teaching Hospital. The second aim was to determine the prevalence of PIVC bacterial colonization. A total of 76 dogs and 40 cats with PIVCs were evaluated for the occurrence of phlebitis and mechanical complications. The devices were removed when they ceased to be functional or when complications occurred, and the content was submitted for bacterial cultures and antimicrobial susceptibility tests. Both multivariable linear regression models and ROC analysis were employed. Complications were recorded in 46.6% of cases, and 20.7% of catheters yielded a positive culture. Among the isolates, 45% were classified as multi-resistant. In dogs, a ≥36-h indwelling time was associated with an increased risk of complications. Male cats seem more prone to developing complications, while the insertion of PIVCs under sedation may represent a protective factor in this species. In conclusion, PIVC-associated complications were frequently observed, and the high rate of positive culture for PIVCs, together with the presence of multi-resistant isolates, is a cause of concern in a hospital setting.Entities:
Keywords: catheters; complications; nosocomial infection; phlebitis
Year: 2022 PMID: 35324846 PMCID: PMC8954030 DOI: 10.3390/vetsci9030118
Source DB: PubMed Journal: Vet Sci ISSN: 2306-7381
Characteristics of sample population.
| Species/Sex | Number of Subjects | Age (months) | Bodyweight (kg) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Total | Un-Neutered | Neutered | Median | Min | Max | Median | Min | Max | |
| Dogs | 76 | 63 | 13 | 60 | 2 | 144 | 14 | 1.5 | 55 |
| Males | 53 | 46 | 7 | 58 | 2 | 144 | 14.3 | 2 | 55 |
| Females | 23 | 17 | 6 | 66 | 3 | 144 | 13.6 | 1.5 | 25 |
| Cats | 40 | 29 | 11 | 54 | 4 | 144 | 3 | 1.5 | 5.5 |
| Males | 28 | 22 | 6 | 56 | 6 | 144 | 3.7 | 1.5 | 5.5 |
| Females | 12 | 7 | 5 | 49 | 4 | 132 | 2.9 | 1.9 | 4 |
Results on the insertion procedure of intravenous catheters and administration of irritant and/or vesicants and antibiotics.
| Variables | Dogs | Cats | |||
|---|---|---|---|---|---|
| N | % | N | % | ||
| Site of insertion | Cephalic vein | 71 | 93% | 36 | 90% |
| Saphenous vein | 5 | 7% | 4 | 10% | |
| Sedation | No | 55 | 72% | 28 | 70% |
| Yes | 21 | 28% | 12 | 30% | |
| Previous placement of PIVC at the same site | No | 57 | 75% | 28 | 70% |
| Yes | 19 | 25% | 12 | 30% | |
| Size of the device | 26 Gauge | 6 | 8% | 2 | 5% |
| 24 Gauge | 4 | 5% | 12 | 30% | |
| 22 Gauge | 38 | 50% | 23 | 58% | |
| 20 Gauge | 28 | 37% | 3 | 8% | |
| Number of attempts | 1 | 67 | 88% | 31 | 78% |
| 2 | 6 | 8% | 4 | 10% | |
| 3 | 3 | 4% | 5 | 13% | |
| Difficulty | Easy | 69 | 91% | 31 | 78% |
| Difficult | 7 | 9% | 9 | 23% | |
| Reaction | No | 61 | 80% | 31 | 78% |
| Mild | 9 | 12% | 7 | 18% | |
| Moderate | 6 | 8% | 1 | 3% | |
| Strong | - | 0% | 1 | 3% | |
| Site quality | Good | 69 | 91% | 35 | 88% |
| Poor | 7 | 9% | 5 | 13% | |
| Vesicants/irritants | No | 37 | 49% | 13 | 33% |
| Yes | 39 | 51% | 27 | 68% | |
| Antibiotics | No | 53 | 70% | 19 | 48% |
| Yes | 23 | 30% | 21 | 53% | |
Intravenous antibiotics administered in dogs and cats.
| Classes | Molecules | Dogs ( | Cats ( |
|---|---|---|---|
| Penicillins | Ampicillin | 3 | 1 |
| Potentiated Penicillins | Ampicillin-sulbactam | 3 | 10 |
| Potentiated Penicillins + Fluoroquinolones | Ampicillin-sulbactam + Enrofloxacin | 1 | 1 |
| Potentiated Penicillins + Nitromidazoles | Ampicillin-sulbactam + Metronidazole | 3 | - |
| 1st Generation Cephalosporins | Cefazolin | 5 | 5 |
| 3rd Generation Cephalosporins | Ceftazidime | 5 | 1 |
| Fluoroquinolones | Enrofloxacin | 3 | 2 |
| Nitromidazoles | Metronidazole | - | 1 |
Figure 1Boxplot of indwelling times of catheters in dogs and cats (red circles indicate the median values of the distribution).
Variables at the time of the catheter removal.
| Variables | Modalities | Dogs | Cats | ||
|---|---|---|---|---|---|
| N | % | N | % | ||
| Visual Infusion Phlebitis scale | Score 0 | 35 | 46% | 9 | 23% |
| Score 1 | 10 | 13% | 14 | 35% | |
| Score 2 | 7 | 9% | 2 | 5% | |
| Score 3 | 15 | 20% | 10 | 25% | |
| Score 4 | 9 | 12% | 5 | 13% | |
| Score 5 | - | - | - | - | |
| Onset of complications | No | 43 | 57% | 19 | 48% |
| Yes | 33 | 43% | 21 | 52% | |
| Complication/reason for removal | Disuse * | 43 | 57% | 19 | 48% |
| Mechanic | 9 | 12% | 6 | 15% | |
| Inflammatory | 7 | 9% | 5 | 12% | |
| Mixed | 17 | 22% | 10 | 25% | |
| Bacterial culture | Negative | 60 | 79% | 32 | 80% |
| Positive | 16 | 21% | 8 | 20% | |
* intended as the primary reason for removal; this category includes 7 dogs and 2 cats which showed a VIP score ≥ 2.
Figure 2Box plot of indwelling time of catheters according to variations of phlebitis scores in dogs (red circles indicate the median values of the distributions).
Figure 3Distribution of the VIP scores according to the indwelling time of catheters. T: indwelling time; VIP: Visual Infusion Phlebitis.
Figure 4Causes of catheter removal according to the permanence time of the device.
Figure 5Receiver operating characteristic (ROC) curves determine the degree of phlebitis (absent–mild phlebitis vs. moderate–severe phlebitis) and indwelling time of catheters in dogs.
Sensitivity and specificity of different cut-off points to prevent the onset of moderate-to-severe phlebitis in dogs.
| Cut-Point (h) | Sensitivity | Specificity | Classified | Youden’s J |
|---|---|---|---|---|
| (≥6) | 100% | 0% | 31.6% | 0.00 |
| (≥12) | 100% | 42.3% | 60.5% | 0.42 |
| (≥13) | 100% | 46.2% | 63.2% | 0.46 |
| (≥20) | 100% | 48.1% | 64.5% | 0.48 |
| (≥23) | 100% | 50.0% | 65.8% | 0.50 |
| (≥24) | 95.8% | 51.9% | 65.8% | 0.48 |
| (≥25) | 79.2% | 69.2% | 72.4% | 0.48 |
| (≥26) | 75.0% | 71.2% | 72.4% | 0.46 |
| (≥27) | 75.0% | 73.1% | 73.7% | 0.48 |
| (≥29) | 75.0% | 75.0% | 75.0% | 0.50 |
| (≥30) | 75.0% | 76.9% | 76.3% | 0.52 |
| (≥32) | 75.0% | 78.9% | 77.6% | 0.54 |
| (≥35) | 75.0% | 80.8% | 79.0% | 0.56 |
| (≥36) | 75.0% | 82.7% | 80.3% | 0.58 |
| (≥38) | 58.3% | 88.5% | 79.0% | 0.47 |
| (≥40) | 54.2% | 88.5% | 77.6% | 0.43 |
| (≥43) | 50.0% | 88.5% | 76.3% | 0.38 |
| (≥47) | 50.0% | 90.4% | 77.6% | 0.40 |
| (≥48) | 50.0% | 92.3% | 79.0% | 0.42 |
| (≥60) | 20.8% | 100% | 75.0% | 0.21 |
| (≥74) | 16.7% | 100% | 73.7% | 0.17 |
| (≥96) | 12.5% | 100% | 72.4% | 0.13 |
| (≥108) | 8.3% | 100% | 71.1% | 0.08 |
| (≥132) | 4.2% | 100% | 69.7% | 0.04 |
| (>132) | 0% | 100% | 68.4% | 0.00 |
Phenotypic resistance profiles of multiresistant isolates.
| Isolate | Species | PEN | AMI | MAC | CEF-1 | CEF-2 | CEF-3 | CEF-4 | FLUO | LINC | SXT | CARB | Tot. Classes R |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
| D | R | R | S | - | R | R | S | R | - | S | - | 5 |
|
| D | R | R | S | - | R | R | - | R | - | S | R | 6 |
|
| C | R | S | S | - | R | S | S | S | - | S | R | 3 |
|
| C | R | S | S | - | R | S | S | S | - | S | R | 3 |
|
| C | R | S | S | - | R | S | S | S | - | S | R | 3 |
|
| D | R | S | R | R | R | S | R | S | - | S | - | 5 |
|
| D | - | S | - | - | - | R | R | S | - | - | R | 3 |
|
| D | - | R | - | - | - | S | S | R | - | - | R | 3 |
|
| D | S | R | S | R | S | S | S | S | - | R | - | 3 |
| D | R | S | S | R | R | R | R | R | R | S | - | 7 |
D, dog; C, cat; R, resistant to tested antimicrobial class; -, non-tested class; S, sensible; PEN, potentiated penicillin; AMI, aminoglycosides; MAC macrolides; CEF-k, cephalosporins, FLUO, fluoroquinolones; LINC, lincosamides, SXT potentiated sulfonamides; CARB, carbapenems.